Research
Hormonal
Activation of Gq-coupled receptors in brown and beige adipocytes generally suppresses thermogenic competence, whereas specific Gq receptors (like GPR120) can boost lipid oxidation and mitochondrial respiration.
The role of Gq receptors in fat burning is complex. While some Gq receptors (like those activated by acetate) may reduce fat-burning capacity, others (like GPR120, activated by fatty acids) can boost it. This complexity makes it a challenging target for simple drug development.
ModerateQualifiesMEDIUM confidence
The role of Gq-signaling in brown and beige adipocytes appears to be multi-faceted and has been linked to both inhibition and activation of thermogenic competence.
Why this rating
Based on mixed preclinical findings.
Source
Leveraging GPCR signaling in thermogenic fat to counteract metabolic diseases
Olivia Sveidahl Johansen et al. · Molecular Metabolism · 2022
DOI 10.1016/j.molmet.2022.101474
narrative_reviewCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Pharmacological activation of G protein-coupled receptors (GPCRs) in thermogenic brown and beige adipocytes can increase energy expenditure and improve metabolic health, but current adrenergic agonists have a narrow safety window due to cardiovascular side effects.Good
- Non-adrenergic Gs-coupled receptors (e.g., secretin, glucagon, adenosine) can stimulate brown adipose tissue thermogenesis independently of the sympathetic nervous system, offering a potential pathway to avoid cardiovascular side effects associated with adrenergic agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →